# LigaChem Biosciences

Source: https://onco.cc/companies/ligachem-biosciences/  
OnCo record `ligachem-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LigaChem Biosciences is a South Korea-based biotechnology company running 2 late-stage cancer trials of LCB02A and LCB84.

## Summary

LigaChem Biosciences, based in Daejeon, South Korea, is a biotechnology company. LigaChem Biosciences is a biotech company focused on drug research and development, specialising in antibody-drug conjugate (ADC) therapeutics, small molecule immunotherapies and synthetic drug development. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LCB02A and LCB84. The largest, NCT05941507 (A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumours), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: LigaChem Biosciences, Inc.
- Tags: ctgov-sponsor
- HQ: Daejeon
- Type: biotech
- Website: https://www.ligachembio.com

## Sources

- Official website: https://www.ligachembio.com
- ClinicalTrials.gov: trials led by LigaChem Biosciences: https://clinicaltrials.gov/search?lead=LigaChem%20Biosciences%2C%20Inc.

## Connected records

- drugs: [LCB02A](https://onco.cc/drugs/lcb02a/), [LCB84](https://onco.cc/drugs/lcb84/)
- trials: [A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors](https://onco.cc/trials/nct07460375/), [A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors](https://onco.cc/trials/nct05941507/)

---
JSON: https://onco.cc/api/v1/entities/ligachem-biosciences.json